Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 11.10%. However, over the last six months, the performance has been stronger by -44.22%. The price of CARA decreased -21.38% over the last 30 days. And in the last five days, it has fallen by -9.29%.
Cara Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $4.75 on 05/16/23, while the lowest price for the same period was registered at $0.50 on 01/25/24.
52-week price history of CARA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cara Therapeutics Inc’s current trading price is -82.62% away from its 52-week high, while its distance from the 52-week low is 65.10%. The stock’s price range during this period has varied between$0.50 and $4.75. The Cara Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.58 million for the day, a figure considerably lower than their average daily volume of 0.7 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cara Therapeutics Inc (CARA) has experienced a quarterly rise of 34.58% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 45.12M and boasts a workforce of 55 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.8133, with a change in price of -0.2245. Similarly, Cara Therapeutics Inc recorded 798,393 in trading volume during the last 100 days, posting a change of -21.38%.
CARA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CARA stands at 0.76. Similarly, the long-term debt-to-equity ratio is also 0.76.
CARA Stock Stochastic Average
As of today, Cara Therapeutics Inc’s raw stochastic average for the last 50 days stands at 48.90%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 35.71%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 34.39% and 38.65%, respectively.
